GeneDx Holdings Corp.

WGSReported to SECin USCIK 0001818331Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 26. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 26
Form 4 lines at GeneDx Holdings Corp., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Fuchs Thomas—Option exercisenothing paid1,146 sharesSep 18, 2026Fuchs Thomasnothing paidExercise · Sep 18Option exercise1,146Sep 18, 2026
Fuchs Thomas—Option exercisenothing paid1,146 sharesSep 18, 2026Fuchs Thomasnothing paidExercise · Sep 18Option exercise1,146Sep 18, 2026
Feeley KevinCHIEF FINANCIAL OFFICEROption exercisenothing paid7,197 sharesSep 18, 2026Feeley KevinCHIEF FINANCIAL OFFICERnothing paidExercise · Sep 18Option exercise7,197Sep 18, 2026
Feeley KevinCHIEF FINANCIAL OFFICEROpen-market sell$106,8161,079 sharesSep 18, 2026Feeley KevinCHIEF FINANCIAL OFFICER$106,816Sell · Sep 18Open-market sell1,079Sep 18, 2026
Feeley KevinCHIEF FINANCIAL OFFICEROpen-market sell$144,4571,470 sharesSep 18, 2026Feeley KevinCHIEF FINANCIAL OFFICER$144,457Sell · Sep 18Open-market sell1,470Sep 18, 2026